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Enterohemorrhagic
Escherichia coli
O157, Kinshasa 
To the Editor: During the rainy
season, from April to September
2003, 463 children ≤15 years of age
(median 10 months) with severe
diarrhea were admitted to the
Pediatric Hospital of Kalembelembe
in Kinshasa, the capital of the
Democratic Republic of Congo. The
population of the outbreak area was
approximately one million.
Several children with bloody
diarrhea without fever were treated.
They came from six districts of
Kinshasa (Bumbu, Selembao,
Makala, Kimbanseke, Masina, and
Ndjili). Abdominal cramps, nausea,
vomiting, and dehydration were
uncommon. The duration of illness
ranged from 5 days to 2 weeks.
Available antiparasitic drugs,
trimethoprim-sulfamethoxazole, and
ampicillin showed no effect against
the illness. Fifty-six infants died
between June and July. Symptoms of
hemolytic uremic syndrome deve-
loped in most of them.
Stool samples from 32 patients
were screened for parasites,
enteropathogenic bacteria, rotavirus,
and adenovirus. Three samples were
positive for rotavirus. In contrast, all
stool cultures were positive for
Escherichia coli which always grew
as pure cultures on purple bromocre-
sol agar, a nonselective medium con-
taining lactose. The E. coli isolates
appeared sorbitol negative when test-
ed on MacConkey sorbitol; they were
agglutinated by O157 and H7 antisera
(Difco Laboratories, Detroit, MI) and
lacked expression of β-glucuronidase.
All E. coli isolates were sent to the
Pasteur Institute in Bangui, Central
African Republic, for further charac-
terization. Polymerase chain reaction
allowed detection of Shiga-like toxin
slt-1 and slt-2 genes (1,2) in isolates
from all patients. The Vero cell assay
phenotypically confirmed cytotoxici-
ty of these isolates, with most of them
being seroneutralized by rabbit antis-
era against Shiga toxin (3). Thus, all
E. coli isolates responded to the defi-
nition of enterohemorrhagic E. coli.
Before 2003, sporadic infections
or outbreaks caused by enterohemor-
rhagic E. coli were not reported as a
cause of bloody diarrhea in the
Democratic Republic of Congo. A
case-control study could not be per-
formed because of political unrest in
Kinshasa. Although reported out-
breaks of E. coli O157 in sub-Saharan
Africa have been few to date, avail-
able information indicates that the
pathogen has wide geographic distri-
bution. E. coli O157–related diarrhea
outbreaks that occurred before 2003
have been reported in South Africa,
Swaziland (4), and Malawi (5) in
1992; Central African Republic (6)
and Kenya (7) in 1996; Cameroon in
1998 (8); and Nigeria (9) and Ivory
Coast (10) in 2000. In the Central
African Republic and in Zémio, a
small village located on the
Democratic Republic of Congo bor-
der, outbreaks of bloody diarrhea in
1996 were attributed to E. coli O157
from molecular test results (6).
Since 2001, an increasing number
of cases of acute bloody diarrhea have
been reported in Kinshasa between
June and August. During this 2003
outbreak, an investigation could not
be conducted; possible routes of
transmission would include person-
to-person contact related to lack of
hygiene, and contaminated food and
water.
In 1996 in the Central African
Republic and in 1998 in Cameroon,
the major contributing factors of the
E. coli O157 outbreak were consump-
tion of smoked zebu meat and con-
taminated drinking water. Studies of
E. coli O157 carriage rates among
livestock, food, and environment in
this central African area might be use-
ful in assessing the potential for future
outbreaks.
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Hemolytic uremic syndrome occurs
in approximately 8% of children and
an unknown proportion of adults
infected with E. coli O157 and can be
fatal without hemodialysis. The high
death rate of infants during this out-
break was linked to the lack of treat-
ment (mainly hemodialysis) at the
beginning of the epidemic.
Obviously, more work is needed to
better define the incidence and epi-
demiology of E. coli–associated diar-
rhea in the Democratic Republic of
Congo so that optimal recommenda-
tions for preventing and managing ill-
ness can be developed.
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Iatrogenic
Mycobacterium
simiae Skin
Infection in an
Immunocompetent
Patient 
To the Editor: We report a case of
a 36-year-old woman who sought
treatment for 45 firm and erythema-
tous nodular lesions on her face and
neck. A physical examination showed
no other abnormalities. Results of a
chest x-ray and routine laboratory
tests were normal. The patient tested
negative for hepatitis B and HIV.
Three weeks before she sought treat-
ment, the patient reported receiving
multiple intradermal microinjections
in her face and neck for cosmetic pur-
poses (mesotherapy) with an unli-
censed product consisting of a solu-
tion of glycosaminoglycans. The
injections had been administered by
an unlicensed practitioner in a non-
medical office setting. The patient
stated that 2 days after the therapy, a
fever developed; it persisted for sev-
eral days, along with redness at the
inoculation sites, which gradually
developed into nodules. 
Standard staining of a biopsied
specimen from the lesion site was
negative for bacteria, fungi, and
mycobacteria. A histopathologic
examination of a biopsy specimen
showed an unspecific granulomatous
infiltrate. Culture for common bacte-
ria and fungi was negative, but culture
of a sterile nodule aspirate on
Lowenstein-Jensen medium was posi-
tive for acid-fast bacteria after 5
weeks. By using restriction endonu-
clease analysis of the 65-kDa heat
shock protein gene (1), we found that
the isolate showed a pattern compati-
ble with Mycobacterium simiae.
Identification was subsequently con-
firmed by high performance liquid
chromatography of mycolic acids at
the Centers for Disease Control and
Prevention, Atlanta, Georgia. The iso-
late was tested for drug susceptibility
against a panel of drugs and found to
be resistant to most drugs tested
(streptomycin, isoniazid, rifampin,
ethambutol, ethionamide, rifabutin,
ciprofloxacin, kanamycin, capre-
omycin, p-aminosalicylic acid,
ofloxacin, and amikacin) and suscep-
tible to clarithromycin at an MIC of 1
µg/mL. Treatment with clar-
ithromycin was started, and the gran-
ulomas slowly cleared after 9 months
of treatment. 
To our knowledge, this is the first
reported case of an iatrogenic skin
infection caused by M. simiae in an
immunocompetent person. M. simiae
is a species of nontuberculous
mycobacterium commonly found in
nature, but its role as a pathogen has
been controversial. The slow-grow-
ing, photochromogenic mycobacteri-
um has been isolated from both sur-
face and tap water and has been asso-
ciated with a nosocomial pseudo-out-
break suspected to have originated
from a contaminated hospital water
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